Literature DB >> 2875942

DNA typing of HLA-DR antigens in systemic lupus erythematosus.

H Dunckley, P A Gatenby, S W Serjeantson.   

Abstract

HLA-DR typing is technically difficult in systemic lupus erythematosus (SLE), where patients have low numbers of peripheral B cells, often of poor viability and weak in antigenic expression. In this series, one third of SLE patients could not be HLA-DR typed by serological techniques, highlighting the potential for systematic bias in DR antigen assignment in studies of HLA and SLE. This potential bias was examined by comparing serological DR results with DNA-DR typing, achieved by examining Taq I fragments of DR beta, DQ alpha, and DQ beta which permitted unequivocal DR phenotyping of all patients, including the 35% for whom conventional DR typing was technically impossible. This showed the success of serological DR antigen assignment was indeed nonrandom, with HLA-DR2 and -DR3 significantly more readily identifiable than DR5 and DRw13. Our study suggests that technical problems may well have contributed to conflicting reports regarding the association of DR2 or DR3 with SLE. Here, DNA-DR phenotyping showed HLA-DR3 is significantly (P less than .05) associated with an increased risk for SLE (54% in 46 patients, 36% in 134 controls) and HLA-DR2 is not.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875942     DOI: 10.1007/bf00364743

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  25 in total

Review 1.  Structure, sequence and polymorphism in the HLA-D region.

Authors:  J Trowsdale; J A Young; A P Kelly; P J Austin; S Carson; H Meunier; A So; H A Erlich; R S Spielman; J Bodmer
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 12.988

2.  B-lymphocyte alloantigens associated with systemic lupus erythematosus.

Authors:  J L Reinertsen; J H Klippel; A H Johnson; A D Steinberg; J L Decker; D L Mann
Journal:  N Engl J Med       Date:  1978-09-07       Impact factor: 91.245

3.  HLA-D and Ia antigens in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  P Stastny
Journal:  Arthritis Rheum       Date:  1978-06

4.  Corticosteroids decrease the expression of beta 2-microglobulin and histocompatibility antigens on human peripheral blood lymphocytes in vitro.

Authors:  M Hokland; B Larsen; I Heron; T Plesner
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

Review 5.  Systemic lupus erythematosus: current state of the genetic hypothesis.

Authors:  F C Arnett; J D Reveille; R W Wilson; T T Provost; W B Bias
Journal:  Semin Arthritis Rheum       Date:  1984-08       Impact factor: 5.532

6.  Interrelationships of HLA-DR, MB, and MT phenotypes, autoantibody expression, and clinical features in systemic lupus erythematosus.

Authors:  J M Ahearn; T T Provost; C A Dorsch; M B Stevens; W B Bias; F C Arnett
Journal:  Arthritis Rheum       Date:  1982-09

7.  Prevalence of HLA-DRw2 not increased in systemic lupus erythematosus.

Authors:  O Scherak; J S Smolen; W R Mayr
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

8.  Increased frequency of HLA-DRw3 in systemic lupus erythematosus.

Authors:  A Celada; C Barras; G Benzonana; M Jeannet
Journal:  N Engl J Med       Date:  1979-12-20       Impact factor: 91.245

9.  Six HLA-D region alpha-chain genes on human chromosome 6: polymorphisms and associations of DC alpha-related sequences with DR types.

Authors:  R S Spielman; J Lee; W F Bodmer; J G Bodmer; J Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Both alpha and beta chains of HLA-DC class II histocompatibility antigens display extensive polymorphism in their amino-terminal domains.

Authors:  L Schenning; D Larhammar; P Bill; K Wiman; A K Jonsson; L Rask; P A Peterson
Journal:  EMBO J       Date:  1984-02       Impact factor: 11.598

View more
  9 in total

1.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

2.  HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus.

Authors:  H A Stephens; N J McHugh; P J Maddison; D A Isenberg; K I Welsh; G S Panayi
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 3.  DNA polymorphism and the study of disease associations.

Authors:  D N Cooper; J F Clayton
Journal:  Hum Genet       Date:  1988-04       Impact factor: 4.132

4.  Gm typing by immunoglobulin heavy-chain gene RFLP analysis.

Authors:  E C Jazwinska; H Dunckley; D N Propert; P A Gatenby; S W Serjeantson
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

5.  Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication.

Authors:  E C Jazwinska; C Olive; P M Hogarth; P A Gatenby; S W Serjeantson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

Review 6.  Unraveling the genetics of systemic lupus erythematosus.

Authors:  John B Harley; Jennifer A Kelly; Kenneth M Kaufman
Journal:  Springer Semin Immunopathol       Date:  2006-09-22

7.  Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility.

Authors:  D De Juan; J M Martín-Villa; J J Gómez-Reino; J L Vicario; A Corell; J Martínez-Laso; D Benmammar; A Arnaiz-Villena
Journal:  Hum Genet       Date:  1993-07       Impact factor: 4.132

8.  Polymorphism of the DQA1 promoter region (QAP) and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. SLE Study Group members.

Authors:  Z Yao; A Kimura; K Hartung; P J Haas; A Volgger; G Brünnler; J Bönisch; E D Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

9.  Association between a T cell receptor restriction fragment length polymorphism and systemic lupus erythematosus.

Authors:  J G Tebib; J Alcocer-Varela; D Alarcon-Segovia; P H Schur
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.